![Placeholder Image Placeholder Image](https://prod.arctic.novartis.com/sites/novartis_com/files/placeholder.jpeg)
Tags Archive Navigation
icon
-
Media ReleaseNovartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019
-
Media ReleaseSandoz completes acquisition of Aspen’s Japanese operations, strengthening its position in world’s third largest market for generics and off-patent medicines
-
Media ReleaseNovartis receives EC Approval for Beovu®, a next-generation anti-VEGF treatment for wet AMD, a leading cause of blindness worldwide
-
Media ReleaseNovartis announces FDA and EMA filing acceptance of ofatumumab, a novel B-cell therapy for patients with relapsing forms of multiple sclerosis (RMS)
-
Media ReleaseLes actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration à l’Assemblée générale annuelle
-
Media ReleaseNovartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
-
Media ReleaseAveXis receives positive CHMP opinion for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA)
-
Media ReleaseNovartis Cosentyx® gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum
-
Media ReleaseNovartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
-
Media ReleaseNovartis acquires Amblyotech, pursuing novel digital therapy for children and adult patients with “lazy eye”
-
Media ReleaseNovartis announces data showing Jakavi® (ruxolitinib) more effective than best available therapy in acute graft-versus-host disease
-
Media ReleaseNovartis Cosentyx® gains fourth indication in EU with first-in-class approval in axial spondyloarthritis spectrum
Pagination
- ‹ Previous page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- › Next page